Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer

Abstract

Purpose A prospective, multicenter, large-scale cohort with a nested case–control study (NCT00252759) was conducted to identify and quantify risk factors for interstitial lung disease (ILD) in Japanese patients with non-small-cell lung cancer who received gefitinib. This study reports the association between gefitinib exposure and the occurrence of ILD. Methods A total of 1891 gefitinib plasma concentrations from 336 patients were measured after first dose, at steady state, and at time of ILD occurrence. Influences of demographic and pathophysiological factors on pharmacokinetics were investigated by non-linear mixed-effect modeling. The exposure to gefitinib was compared between patients without and with ILD occurrence to explore risks associated with gefitinib-induced ILD. Intra-patient comparison of exposure was also conducted between times at ILD development and normal states. Results In the population pharmacokinetic analysis for gefitinib, α 1 -acid glycoprotein (AGP), age, body weight, and concomitant use of cytochrome P450 3A4 inducers were significant covariates on oral clearance (CL/F). AGP and body weight were also identified as factors affecting the volume of distribution. CL/F was significantly lower at the time of ILD occurrence than normal states. Patients who developed ILD tended to show higher exposure to gefitinib than those without ILD; however, these differences were not statistically significant. On the other hand, exposure at the time of ILD occurrence was significantly elevated compared to the time of normal state within the same patients. Conclusions Significant elevation of exposure of gefitinib was observed at the time of ILD occurrence, suggesting reduction of CL/F could be associated with ILD-induced AGP elevation. Increase in exposure of gefitinib is unlikely to be a robust predictor of ILD and does not warrant any dose modifications. Electronic supplementary material The online version of this article (10.1007/s00280-019-03788-4) contains supplementary material, which is available to authorized users.

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan

“…The ILD rate associated with osimertinib in this analysis was 6.8%, and fatal outcomes resulting from ILD occurred in 0.8% (11.8% of the ILD population). In post-marketing studies of gefitinib, erlotinib or afatinib, ILD rates ranging from 4.3 to 15.2% have been reported ( 28–30 ). In terms of ILD mortality rate, among the latter studies, the death rate from ILD was 1.5% (153/9909) (i.e.…”

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study

“…The AUC 0–24 value of gefitinib observed in patients with a median age of 61 years (range, 41–73 years) at a dose of 225 mg was 1986 ng h/mL which is equivalent to 4.44 µM h. Because the relationship between the gefitinib dose and its AUC were reported to be linear [ 23 , 24 ], the AUC 0–24 value of gefitinib at a dose of 250 mg in younger patients was estimated to be 4.9 µM h, which is somewhat lower than the 6.17 ± 1.9 µM h obtained in elderly patients. A population pharmacokinetic analysis revealed that the CL/F value of gefitinib was negatively correlated with age [ 25 ]. Taking these results into account, systemic exposure to gefitinib in elderly patients may be slightly higher than that in younger patients.…”

Simultaneous and Rapid Determination of Six Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Using HPLC-MS/MS

“…e drug exposure in vivo has a close relation with the treatment efficacy and/or adverse reaction, and it was still the key point for the clinical optimization of drug dose [17][18][19][20][21]. ere were differences in drug absorption, distribution, metabolism, and excretion between patients and within patients, and several studies in recent years were also reported [22][23][24].…”